Immuron (IMRN) Capital Expenditures (2016 - 2022)

Name: Immuron (IMRN) Capital Expenditures (2016 - 2022) | Business Quant
Creator: Business Quant

Immuron's quarterly Capital Expenditures came in at -$7067.0 in Q4 2022, down 6.59% quarter-over-quarter from -$6630.0 in Q4 2020.

Immuron has reported Capital Expenditures for 5 years, with the latest figure at -$7067.0 in Q4 2022.

For the quarter ending Q4 2022, Capital Expenditures changed N/A year-over-year to -$7067.0; the trailing twelve-month figure through Dec 2022 stood at -$16260.0 (changed N/A YoY), and the FY2025 full-year result was -$3.0 million, down 1556965.64% from the prior year.
Capital Expenditures for Q4 2022 stood at -$7067.0, down from -$6630.0 in the prior quarter.
The five-year high for Capital Expenditures was -$864.0 in Q4 2019, with the low at -$7067.0 in Q4 2022.
Average Capital Expenditures over 3 years is -$4853.7, with a median of -$6630.0 recorded in 2020.
Peak annual rise in Capital Expenditures reached 667.36% in 2020, while the deepest fall reached 667.36% in 2020.
Tracing IMRN's Capital Expenditures over 3 years: stood at -$864.0 in 2019, then sank by 667.36% to -$6630.0 in 2020, then slipped by 6.59% to -$7067.0 in 2022.
The last three Capital Expenditures figures came in at -$7067.0 (Q4 2022), -$6630.0 (Q4 2020), and -$864.0 (Q4 2019), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	133.40 Mn
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	230.60 Mn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	21.83 Mn
10	Immuron	1.27 Bn	1.27 Bn	-	-

Download Data 🔒